Comparison · NCT02429427-0ed95a71
Celecoxib vs Placebo: Number of Participants With Incidence of Second Primary Breast Cancers
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Celecoxib vs Placebo: Number of Participants With Incidence of Second Primary Breast Cancers. Trial comparisons, record NCT02429427-0ed95a71. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02429427-0ed95a71
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0108 | 0.00691 | 0.0168 | wilson | |
| Risk in group 2 | 0.0137 | 0.00785 | 0.0238 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00292 | -0.0137 | 0.00545 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.787 | 0.384 | 1.61 | log | |
| Odds ratio, group 1 over group 2 | 0.784 | 0.379 | 1.62 | log | |
| Number needed to treat, for one fewer participant with the outcome on Celecoxib than on Placebo | 342 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Celecoxib | Patients in this arm will receive 400mg of celecoxib once daily. In addition, Hormone Receptor (+) patients will receive endocrine treatment according to local practice.~Celecoxib: Patients will receive 400mg of Celecoxib once daily for two years or until disease progression (if before the two years limit) or until development of unacceptable toxicities. In addition ER(+) patients will receive endocrine treatment according to local practice. | 19 | 1,763 | OG000 |
| Group 2 | Placebo | Patients in this arm will receive 2 tablets once daily. In addition Hormone Receptor (+) patients will receive endocrine treatment according to local practice.~Placebo: Two capsules once daily with food | 12 | 876 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Incidence of Second Primary Breast Cancers
- Description
- Any malignant contralateral breast disease will be included and recorded as a second primary
- Time frame
- From randomisation until a second primary breast cancer is diagnosed. Patients will be followed up to 10 years.
- Population
Intention To Treat: This population includes all patients entered into the study in the treatment group they were allocated to regardless of whether they do not start treatment, take the wrong treatment or deviate in any way from the protocol.
Source ClinicalTrials.gov
Trial
- Title
- European Celecoxib Trial in Primary Breast Cancer
- NCT number
- NCT02429427
- Phases
- PHASE3
- Conditions
- Breast Cancer
- Interventions
- Celecoxib, Placebo
- Lead sponsor
- Imperial College London
- Results first posted
- 2020-06-23
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02429427?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02429427-0ed95a71